Digital Sedation Opportunity Oncomfort offers a non-pharmacological digital sedation solution using Virtual Reality and clinical hypnotherapy, presenting a compelling alternative or adjunct to pharmacological sedatives for pain and anxiety relief during medical procedures. Potential sales play: target hospitals, clinics, and procedure centers seeking non-drug comfort options to improve patient experience and throughput.

Strategic Partnerships Past and potential partners include medical device distributors and healthcare providers (example: Vygon SA for Sedakit distribution). Value proposition for channel partnerships includes expanding geographic reach, accelerating adoption in Europe, and leveraging existing sales networks to penetrate hospitals and outpatient centers.

Growth through Acquisitions Industry activity indicates consolidation in digital sedation space, with Hypnovr acquiring Oncomfort. This trend suggests opportunity for co-selling, integration discussions, or collaboration with acquirers or portfolio companies seeking complementary digital therapeutics assets.

Clinical Validation Channel Oncomfort has a track record of adoption across a range of procedures and patient groups, including cancer and heart disease, with demonstrated usage in tens of thousands of sessions. Leverage clinical case studies, awards, and regulatory/clinical validation to support ROI-focused pitches to hospital procurement and anesthesiology teams.

Financial and Market Readiness With funding of around $15M and revenue under $1M, the company is in early commercialization but backed by credible investors. Emphasize total cost of ownership, patient throughput improvements, and potential payor or hospital budget impact to unlock pilot deployments and expansion into new European markets where Sedakit has previously launched.